American Health Intel Rules. Money. Medicine. Decoded daily.
Subscribe
← All editions
Following a story · 2 updates

FDA refuses approval of Capricor's Duchenne heart therapy

Aug 21, 2026 – Nov 22, 2026

  1. Aug 21, 2026 The Regulator Deadline

    FDA faces August 22 deadline on first Duchenne heart-damage therapy

    The FDA's PDUFA target action date on Capricor Therapeutics' deramiocel arrives August 22, three weeks after the agency's advisory committee voted 9 to 3 that the evidence did not support approval.

    Read this issue →
  2. Nov 22, 2026 The Regulator Approval Latest

    FDA refuses approval of Capricor's Duchenne heart therapy

    Capricor said the FDA issued a Complete Response Letter on deramiocel on November 20, stating the data are not sufficient to establish substantial evidence of effectiveness, and the company reported about $198.5 million in cash and securities on September 30.

    Read this issue →